Behavioural Brain Research · 2015 · 50 citations · 30 references
Life SciencesNeurosciencePharmacologyMolecular NeuroscienceNeurodegenerationNeuropharmacologyGlutamatergic SignalingNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionNeuroprotective PharmacologyParkinson DiseaseDopaminergic NeuroprotectionGlp-1 Receptor PharmacologyGlutamatergic NeuroprotectionNeuroprotection Via Glutamate ModulationNeuroprotective MechanismsNeuroprotective SignalingParkinsonian Neuroprotection
30
Yazhou Li, TracyAnn Perry, Mark S. Kindy et al. · Proceedings of the National Academy of Sciences · 2009 · 576 citations · Full text
Exenatide and the treatment of patients with Parkinson’s disease
Icíar Avilés-Olmos, John Dickson, Zinovia Kefalopoulou et al. · Journal of Clinical Investigation · 2013 · 514 citations
Medicine, Neurology, Pharmacology +17
Type 2 Diabetes and the Risk of Parkinson's Disease
Gang Hu, Pekka Jousilahti, Siamak Bidel et al. · Diabetes Care · 2007 · 466 citations · Full text